---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/100000000756957.md"
description: "📢 𝐉𝐔𝐒𝐓 𝐈𝐍: Eli Lilly Plans Europe Launch of Weight-Loss Pill in Late 2026 or Early 2027 - $Eli Lilly(LLY.US) $Novo Nordisk AS(NVO.US) $Hims & Hers Health(HIMS.US) 👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:➤  𝐄𝐥𝐢 𝐋𝐢𝐥𝐥𝐲 plans to launch its weight-loss pill in Europe and Britain in 𝐇𝟐 𝟐𝟎𝟐𝟔 or early 𝟐𝟎𝟐𝟕.➤  Launch timing depends on obtaining 𝐫𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 approvals across target markets.➤  Lilly will initially target the 𝐨𝐮𝐭-𝐨𝐟-𝐩𝐨𝐜𝐤𝐞𝐭 telehealth market.➤  Strategy mirrors Lilly's 𝐔.𝐒. direct-to-consumer obesity business model.➤  The company plans partnerships with 𝐭𝐞𝐥𝐞𝐡𝐞𝐚𝐥𝐭𝐡 providers and digital health platforms.➤  Lilly says obesity treatment outside the U.S. is largely 𝐩𝐚𝐭𝐢𝐞𝐧𝐭-𝐩𝐚𝐢𝐝.➤  The drug recently secured approvals in the 𝐔.𝐒. and 𝐔𝐀𝐄.➤  Lilly will continue pursuing 𝐠𝐨𝐯𝐞𝐫𝐧𝐦𝐞𝐧𝐭 reimbursement where available.➤  U.S. 𝐦𝐨𝐬𝐭-𝐟𝐚𝐯𝐨𝐮𝐫𝐞𝐝-𝐧𝐚𝐭𝐢𝐨𝐧 pricing policies may affect negotiations.👉 𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬:➤  Expands Lilly's presence in the rapidly growing 𝐠𝐥𝐨𝐛𝐚𝐥 obesity treatment market.➤  Telehealth-focused distribution could accelerate 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 access and adoption.➤  European expansion may create a significant new 𝐫𝐞𝐯𝐞𝐧𝐮𝐞 opportunity for Lilly.👉 𝐄𝐱𝐩𝐞𝐫𝐭 𝐒𝐭𝐚𝐭𝐞𝐦𝐞𝐧𝐭:➤  "Our goal will still be public coverage, wherever possible." — 𝐏𝐚𝐭𝐫𝐢𝐤 𝐉𝐨𝐧𝐬𝐬𝐨𝐧, Executive Vice President of Lilly's International Businesses.➤  "MFN will play a role for all launches." — 𝐏𝐚𝐭𝐫𝐢𝐤 𝐉𝐨𝐧𝐬𝐬𝐨𝐧."
datetime: "2026-06-23T16:25:50.000Z"
locales:
  - [en](https://longbridge.com/en/topics/100000000756957.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/100000000756957.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/100000000756957.md)
author: "[Hardik Shah](https://longbridge.com/en/profiles/27423834.md)"
generator: "portal-rs"
---

# 📢 𝐉𝐔𝐒𝐓 𝐈𝐍: Eli Lilly Plans Europe Launch of Weight…


### Related Stocks

- [HIMS.US](https://longbridge.com/en/quote/HIMS.US.md)
- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**